Contraline closes $92.5M Series B to fund male contraception; Novartis begins Phase 3 actinium therapies; Tavo gets $17M Series A.
June 2, 2026 10:43 AM EDT
News Briefing
Male contraception startup closes $92.5M Series B; Novartis bets on actinium in Phase 3
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
Contraline and its male birth control candidate rally $92.5M amid push into 'massive white space' of men's health
Convergent Therapeutics Announces Positive Phase 2 Data at ASCO 2026 Showing Promising Anti-Tumor Activity, Durability, and Favorable Tolerability for CONV01-α in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer (mCRPC)
ASCO: Sac-TMT’s massive phase 3 program has a jarring gap. Does Merck plan to close it?
ASCO: Pfizer one-ups J&J with Talzenna combo's broad castration-sensitive prostate cancer win
Advanced NanoTherapies Secures Over $31M Series B to Deliver First-of-its-Kind Dual-Drug (Paclitaxel and Sirolimus) Nanoparticle-Coated Balloon Platform for Vascular Treatment
AstraZeneca gains 2nd bladder cancer nod in key expansion for Imfinzi
Novartis experimental actinium-based drug shows promise in prostate cancer treatment: Study
Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice
ASCO: Revolution Medicines confident in RAS leadership as rivals square up
Ratio Therapeutics and PharmaLogic Expand Manufacturing Collaboration to Support Clinical Development of [Ac-225]RTX-2358
